A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies

NCT04532281 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma of Soft Tissue

Interventions

DRUG: Murine CD19 CAR-T cells

Sponsor

Zhejiang University

Collaborators

[object Object]